BRAF inhibitor vemurafenib improves the antitumor activity of adoptive cell immunotherapy

Combining immunotherapy with targeted therapy blocking oncogenic BRAF(V600) may result in improved treatments for advanced melanoma. Here, we developed a BRAF(V600E)-driven murine model of melanoma, SM1, which is syngeneic to fully immunocompetent mice. SM1 cells exposed to the BRAF inhibitor vemura...

Disgrifiad llawn

Wedi'i Gadw mewn:
Manylion Llyfryddiaeth
Prif Awduron: Koya, Richard C., Mok, Stephen, Otte, Nicholas, Blacketor, Kevin J., Comin-Anduix, Begonya, Tumeh, Paul C., Minasyan, Aspram, Graham, Nicholas A., Graeber, Thomas G., Chodon, Thinle, Ribas, Antoni
Fformat: Artigo
Iaith:Inglês
Cyhoeddwyd: 2012
Pynciau:
Article
Mynediad Ar-lein:https://ncbi.nlm.nih.gov/pmc/articles/PMC3422880/
https://ncbi.nlm.nih.gov/pubmed/22693252
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/0008-5472.CAN-11-2837
Tagiau: Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!

Eitemau Tebyg